Injectable Drug Delivery Resources

  1. Navigating PFAS "Forever Chemicals" In Medical Devices - What's On The Horizon 9/18/2024

    Gain an understanding of PFAS, their properties, environmental impact, health risks, and regulatory challenges, focusing on the specific implications for the medical device industry.

  2. Selecting Container Closure Components: A Data-Driven Approach To CCI

    Discover an efficient, data-driven process that employs innovative methods to accelerate the selection of a closure containment system that meets the requirements of the modern regulatory landscape.

  3. Early Decisions To De-Risk The Transition To Combination Products

    The injectable product development landscape is changing, and the pressure to accelerate timelines remains constant. What can you do to overcome all the uncertainty and risk?

  4. Evaluating The Impact Of Sterilization Methods On Stopper Performances 3/11/2022

    Three studies focus on a product designed to address unmet needs in subcutaneous drug therapies for chronic diseases, including sterilization methods and a Human Factors evaluation.

  5. Key Financial Considerations For Phase II Clinical Injectable Drug Manufacturing 9/9/2022

    This article highlights the importance of scalability and flexibility in the choice of an early-stage manufacturing strategy and how that decision impacts financial outcomes for a drug development program.

  6. Small-Scale Aseptic Filling Technology Considerations 2/23/2023

    Small-scale aseptic filling presents a unique set of challenges. Learn what to look for when evaluating small-scale aseptic filling technology.

  7. De-Risking FDA Abbreviated New Drug Application (ANDA) Submissions 6/26/2025

    BD’s Vystra™ Disposable Pen for Liraglutide 3.0 mg demonstrated comparable usability to the reference device, helping de-risk ANDA submissions through proactive human factors evaluation.

  8. Drug Formulation Development: Quick Reference Guide 7/11/2022

    This guide shares the steps involved in formulation development, considerations during formulation, and how partnering with an experienced CDMO can lead to a successful commercial product.

  9. Factors To Consider When Selecting A CDMO For Complex Injectables Development And Manufacture 3/1/2022

    The right CDMO partner will have specialized technologies for complex injectable development along with the equipment, facilities and operations to adopt GMP practices with a "laboratory setting."

  10. Unlocking New Possibilities For Treating Rare Genetic Diseases 1/15/2025

    With over 7,000 rare diseases, the potential for nanomedicine to revolutionize treatment is immense. While polymer nanoparticles hold great promise, several challenges remain.